Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Debt to Equity (2017 - 2021)

Sunshine Biopharma's Debt to Equity history spans 5 years, with the latest figure at $8.98 for Q4 2021.

  • For Q4 2021, Debt to Equity rose 1003.17% year-over-year to $8.98; the TTM value through Dec 2021 reached $8.98, up 1003.17%, while the annual FY2021 figure was $8.98, 1003.17% up from the prior year.
  • Debt to Equity reached $8.98 in Q4 2021 per SBFM's latest filing, up from -$2.73 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $8.98 in Q4 2021 to a low of -$5.57 in Q4 2018.
  • Average Debt to Equity over 5 years is -$0.02, with a median of -$0.64 recorded in 2020.
  • Peak YoY movement for Debt to Equity: tumbled 3908.81% in 2018, then skyrocketed 1003.17% in 2021.
  • A 5-year view of Debt to Equity shows it stood at -$0.14 in 2017, then plummeted by 3908.81% to -$5.57 in 2018, then skyrocketed by 99.33% to -$0.04 in 2019, then plummeted by 2580.8% to -$0.99 in 2020, then skyrocketed by 1003.17% to $8.98 in 2021.
  • Per Business Quant, the three most recent readings for SBFM's Debt to Equity are $8.98 (Q4 2021), -$2.73 (Q3 2021), and -$2.35 (Q2 2021).